MELBOURNE, AUSTRALIA--(Marketwire - October 21, 2010) - Biota Holdings Limited (ASX: BTA) today advised that it had received written notification from GlaxoSmithKline (GSK) that, for the three months ended 30 September 2010, Relenza sales were $29.6 million and indicative royalties were $2.1 million. GSK advised that the figures were calculated on an Australian dollar exchange rate of 1.6399 A$ to the UK pound.
Actual payment will be calculated on the exchange rate of 30 April 2011.
Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.
In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir®, is marketed in Japan.
Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.
*Further information available at www.biota.com.au